The Drug Enforcement Administration (DEA) is increasing the 2025 quota for the legal production of DMT in the U.S., saying it agrees with requests for the adjustment to “support legitimate research and scientific efforts” to develop a Food and Drug Administration- (FDA) approved drug based on the psychedelic.
In a notice set to be published in the Federal Register on Tuesday, DEA cited “additional quota applications and comments from DEA-registered manufacturers,” justifying the increase for the psychedelic compound.
DEA released initial quotas for the production of Schedule I and Schedule II controlled substances for research purposes in September. At the time, it called for an increase in the manufacturing of the psychedelics ibogaine, psilocybin and psilocyn, while continuing to maintain stable quotas for other substances such as marijuana, THC and MDMA.
But following a public comment period, it raised the production goal for DMT from 11,000 grams to 20,000 grams.
It’s not clear how close researchers are to developing a DMT-based drug, but several companies have indicated their intent to bring the psychedelic to market, pending regulatory approval.
Hellbound and Down 